Paula Starke
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Paula Starke has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Albert Rosenberger
19University Medical Center Göttingen, Institute of Genetic Epidemiology, Göttingen, Germany
2 shared publications - Heike Bickeböller
19University Medical Center Göttingen, Institute of Genetic Epidemiology, Göttingen, Germany
2 shared publications - Kolja Thormann
Institute of Computer Science, University of Goettingen
2 shared publications - Marcus Baum
University of Goettingen
2 shared publications Viola Tozzi
Department of Genetic Epidemiology, University Medical Center Göttingen, Göttingen, Germany
2 shared publicationsDawid Pieper
Faculty of Health Sciences Brandenburg, Brandenburg Medical School (Theodor Fontane), Institute for Health Services and Health System Research, Rüdersdorf, Germany
1 shared publication
Latest Publications
- Open Access
- 10 June 2025
- Published by Springer Nature in Drugs & Aging
- Vol. 42 (7) , 655-663
Real-World Harm Reduction of Metformin Plus DPP4 Inhibitors versus Metformin Plus Sulfonylureas in Older Adults: A Target Trial Emulation Using German Claims Data
Objective This study complements evidence from randomized controlled trials on the harms (e.g., hypoglycemia) of sulfonylureas compared with dipeptidyl peptidase-4 inhibitors (DPP4i) in the treatment of type 2 diabetes in older adults using real-world data. Existing evidence suggests an increased risk of hypoglycemia, falls, fractures, and cardiovascular events. Methods Using target trial emulation, we analyzed a retrospective cohort drawn from German routine claims data. We included patients older than 65 years who initiated DPP4i (sitagliptin, vildagliptin, or saxagliptin) or sulfonylureas (glibenclamid or glimepirid) as add on to metformin between 2011 and 2018. Confounding was adjusted for through overlap weighting, and the average treatment effects were estimated in the overlap population using generalized linear models. Results Among 171,318 eligible patients, 111,865 (65%) received DPP4i and 59,453 (35%) sulfonylureas. Patients treated with DPP4i had a higher prevalence of all observed comorbidities. Applying overlap weights to adjust for confounding, patients treated with DPP4i had a higher rate of combined all-cause hospitalizations and outpatient visits compared with those treated with sulfonylureas (rate ratio = 1.03, 95% CI 1.02–1.03) in the total population. In contrast, we found a protective effect of DPP4i on the risk for severe hypoglycemia in the subgroups of new users (ratio rate (RR) = 0.51, 95% CI 0.33, 0.76) and patients with severe renal insufficiency (RR = 0.31, 95% CI 0.16, 0.61). Conclusions Deprescribing sulfonylureas and using DPP4i instead may slightly reduce harm in some subgroups of older adults, which supports recommendations of existing lists of potentially inappropriate medications.
- 10 June 2025
- Published by Springer Nature in Drugs & Aging
- Vol. 42 (7) , 655-663
Open AccessReal-World Harm Reduction of Metformin Plus DPP4 Inhibitors versus Metformin Plus Sulfonylureas in Older Adults: A Target Trial Emulation Using German Claims Data
Objective This study complements evidence from randomized controlled trials on the harms (e.g., hypoglycemia) of sulfonylureas compared with dipeptidyl peptidase-4 inhibitors (DPP4i) in the treatment of type 2 diabetes in older adults using real-world data. Existing evidence suggests an increased risk of hypoglycemia, falls, fractures, and cardiovascular events. Methods Using target trial emulation, we analyzed a retrospective cohort drawn from German routine claims data. We included patients older than 65 years who initiated DPP4i (sitagliptin, vildagliptin, or saxagliptin) or sulfonylureas (glibenclamid or glimepirid) as add on to metformin between 2011 and 2018. Confounding was adjusted for through overlap weighting, and the average treatment effects were estimated in the overlap population using generalized linear models. Results Among 171,318 eligible patients, 111,865 (65%) received DPP4i and 59,453 (35%) sulfonylureas. Patients treated with DPP4i had a higher prevalence of all observed comorbidities. Applying overlap weights to adjust for confounding, patients treated with DPP4i had a higher rate of combined all-cause hospitalizations and outpatient visits compared with those treated with sulfonylureas (rate ratio = 1.03, 95% CI 1.02–1.03) in the total population. In contrast, we found a protective effect of DPP4i on the risk for severe hypoglycemia in the subgroups of new users (ratio rate (RR) = 0.51, 95% CI 0.33, 0.76) and patients with severe renal insufficiency (RR = 0.31, 95% CI 0.16, 0.61). Conclusions Deprescribing sulfonylureas and using DPP4i instead may slightly reduce harm in some subgroups of older adults, which supports recommendations of existing lists of potentially inappropriate medications.
- Open Access
- 5 March 2025
- Published by Springer Nature in Research Integrity and Peer Review
- Vol. 10 (1) , 1-7
Analysis of indications for selectively missing results in comparative registry-based studies in medicine: a meta-research study
Background: We assess if there are indications that results of registry-based studies comparing the effectiveness of interventions might be selectively missing depending on the statistical significance (p < 0.05). Methods: Eligibility criteria Sample of cohort type studies that used data from a patient registry, compared two study arms for assessing a medical intervention, and reported an effect for a binary outcome. Information sources We searched PubMed to identify registries in seven different medical specialties in 2022/23. Subsequently, we included all studies that satisfied the eligibility criteria for each of the identified registries and collected p-values from these studies. Synthesis of results We plotted the cumulative distribution of p-values and a histogram of absolute z-scores for visual inspection of selectively missing results because of p-hacking, selective reporting, or publication bias. In addition, we tested for publication bias by applying a caliper test. Results: Included studies Sample of 150 registry-based cohort type studies. Synthesis of results The cumulative distribution of p-values displays an abrupt, heavy increase just below the significance threshold of 0.05 while the distribution above the threshold shows a slow, gradual increase. The p-value of the caliper test with a 10% caliper was 0.011 (k = 2, N = 13). Conclusions: We found that the results of registry-based studies might be selectively missing. Results from registry-based studies comparing medical interventions should be interpreted very cautiously, as positive findings could be a result from p-hacking, publication bias, or selective reporting. Prospective registration of such studies is necessary and should be made mandatory both in regulatory contexts and for publication in journals. Further research is needed to determine the main reasons for selectively missing results to support the development and implementation of more specific methods for preventing selectively missing results.
- 5 March 2025
- Published by Springer Nature in Research Integrity and Peer Review
- Vol. 10 (1) , 1-7
Open AccessAnalysis of indications for selectively missing results in comparative registry-based studies in medicine: a meta-research study
Background: We assess if there are indications that results of registry-based studies comparing the effectiveness of interventions might be selectively missing depending on the statistical significance (p < 0.05). Methods: Eligibility criteria Sample of cohort type studies that used data from a patient registry, compared two study arms for assessing a medical intervention, and reported an effect for a binary outcome. Information sources We searched PubMed to identify registries in seven different medical specialties in 2022/23. Subsequently, we included all studies that satisfied the eligibility criteria for each of the identified registries and collected p-values from these studies. Synthesis of results We plotted the cumulative distribution of p-values and a histogram of absolute z-scores for visual inspection of selectively missing results because of p-hacking, selective reporting, or publication bias. In addition, we tested for publication bias by applying a caliper test. Results: Included studies Sample of 150 registry-based cohort type studies. Synthesis of results The cumulative distribution of p-values displays an abrupt, heavy increase just below the significance threshold of 0.05 while the distribution above the threshold shows a slow, gradual increase. The p-value of the caliper test with a 10% caliper was 0.011 (k = 2, N = 13). Conclusions: We found that the results of registry-based studies might be selectively missing. Results from registry-based studies comparing medical interventions should be interpreted very cautiously, as positive findings could be a result from p-hacking, publication bias, or selective reporting. Prospective registration of such studies is necessary and should be made mandatory both in regulatory contexts and for publication in journals. Further research is needed to determine the main reasons for selectively missing results to support the development and implementation of more specific methods for preventing selectively missing results.
- Open Access
- 4 August 2022
- Published by Springer Nature in BMC Bioinformatics
- Vol. 23 (1) , 1-6
ImputAccur: fast and user-friendly calculation of genotype-imputation accuracy-measures
Background: ImputAccur is a software tool to measure genotype-imputation accuracy. Imputation of untyped markers is a standard approach in genome-wide association studies to close the gap between directly genotyped and other known DNA variants. However, high accuracy for imputed genotypes is fundamental. Several accuracy measures have been proposed, but unfortunately, they are implemented on different platforms, which is impractical. Results: With ImputAccur, the accuracy measures info, Iam-hiQ and r2-based indices can be derived from standard output files of imputation software. Sample/probe and marker filtering is possible. This allows e.g. accurate marker filtering ahead of data analysis. Conclusions: The source code (Python version 3.9.4), a standalone executive file, and example data for ImputAccur are freely available at https://gitlab.gwdg.de/kolja.thormann1/imputationquality.git.
- 4 August 2022
- Published by Springer Nature in BMC Bioinformatics
- Vol. 23 (1) , 1-6
Open AccessImputAccur: fast and user-friendly calculation of genotype-imputation accuracy-measures
Background: ImputAccur is a software tool to measure genotype-imputation accuracy. Imputation of untyped markers is a standard approach in genome-wide association studies to close the gap between directly genotyped and other known DNA variants. However, high accuracy for imputed genotypes is fundamental. Several accuracy measures have been proposed, but unfortunately, they are implemented on different platforms, which is impractical. Results: With ImputAccur, the accuracy measures info, Iam-hiQ and r2-based indices can be derived from standard output files of imputation software. Sample/probe and marker filtering is possible. This allows e.g. accurate marker filtering ahead of data analysis. Conclusions: The source code (Python version 3.9.4), a standalone executive file, and example data for ImputAccur are freely available at https://gitlab.gwdg.de/kolja.thormann1/imputationquality.git.
- Open Access
ImputAccur: fast and user-friendly calculation of genotype-imputation accuracy-measures
Summary: ImputAccur is a software tool for genotype-imputation accuracy-measures. Imputation of untyped markers is a standard approach in genome-wide association studies to close the gap between directly genotyped and other known DNA variants. However high accuracy for imputed genotypes is fundamental. Several accuracy measures have been proposed, but unfortunately, they are implemented on different platforms, which is impractical. With ImputAccur the accuracy measures info, Iam-hiQ and r²based indices can be derived from standard output-files of imputation software. Sample/probe and marker filtering is possible. This allows e.g. accurate marker filtering ahead of data analysis. A Python code is available but also a stand-alone executable file. Availability and Implementation: The source code (Python version 3.9.4), a stand-alone executive file, and example data for ImputAccur are freely available at https://gitlab.gwdg.de/kolja.thormann1/imputationquality.git . Supplementary Information: Supplementary information is available at Bioinformatics online. Contact: arosenb@gwdg.de or koljaalexander.thormann@uni-goettingen.de
Open AccessImputAccur: fast and user-friendly calculation of genotype-imputation accuracy-measures
Summary: ImputAccur is a software tool for genotype-imputation accuracy-measures. Imputation of untyped markers is a standard approach in genome-wide association studies to close the gap between directly genotyped and other known DNA variants. However high accuracy for imputed genotypes is fundamental. Several accuracy measures have been proposed, but unfortunately, they are implemented on different platforms, which is impractical. With ImputAccur the accuracy measures info, Iam-hiQ and r²based indices can be derived from standard output-files of imputation software. Sample/probe and marker filtering is possible. This allows e.g. accurate marker filtering ahead of data analysis. A Python code is available but also a stand-alone executable file. Availability and Implementation: The source code (Python version 3.9.4), a stand-alone executive file, and example data for ImputAccur are freely available at https://gitlab.gwdg.de/kolja.thormann1/imputationquality.git . Supplementary Information: Supplementary information is available at Bioinformatics online. Contact: arosenb@gwdg.de or koljaalexander.thormann@uni-goettingen.de